Crucell N.V. has established two business units for vaccines and proteins in an effort to enhance its focus on specific opportunities for both product units. Mr. Björn Sjöstrand has been appointed to head the Vaccines Business Unit and Mr. Arthur Lahr has been appointed to head the Protein Business Unit. Mr. Sjöstrand was chief executive officer of SBL Vaccines, which was acquired by Crucell in November 2006. Mr. Lahr was Crucell’s chief strategy officer and executive vice president ...